JP2021531312A5 - - Google Patents

Info

Publication number
JP2021531312A5
JP2021531312A5 JP2021504238A JP2021504238A JP2021531312A5 JP 2021531312 A5 JP2021531312 A5 JP 2021531312A5 JP 2021504238 A JP2021504238 A JP 2021504238A JP 2021504238 A JP2021504238 A JP 2021504238A JP 2021531312 A5 JP2021531312 A5 JP 2021531312A5
Authority
JP
Japan
Prior art keywords
influenza
conjugate
influenza virus
agent
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021504238A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531312A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/042715 external-priority patent/WO2020023323A1/en
Publication of JP2021531312A publication Critical patent/JP2021531312A/ja
Publication of JP2021531312A5 publication Critical patent/JP2021531312A5/ja
Priority to JP2023212681A priority Critical patent/JP2024029005A/ja
Pending legal-status Critical Current

Links

JP2021504238A 2018-07-26 2019-07-20 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体 Pending JP2021531312A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023212681A JP2024029005A (ja) 2018-07-26 2023-12-18 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862703534P 2018-07-26 2018-07-26
US62/703,534 2018-07-26
US201962846549P 2019-05-10 2019-05-10
US62/846,549 2019-05-10
PCT/US2019/042715 WO2020023323A1 (en) 2018-07-26 2019-07-20 Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023212681A Division JP2024029005A (ja) 2018-07-26 2023-12-18 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体

Publications (2)

Publication Number Publication Date
JP2021531312A JP2021531312A (ja) 2021-11-18
JP2021531312A5 true JP2021531312A5 (cg-RX-API-DMAC7.html) 2022-07-26

Family

ID=69180703

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021504238A Pending JP2021531312A (ja) 2018-07-26 2019-07-20 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体
JP2023212681A Pending JP2024029005A (ja) 2018-07-26 2023-12-18 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023212681A Pending JP2024029005A (ja) 2018-07-26 2023-12-18 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体

Country Status (7)

Country Link
US (2) US20210393786A1 (cg-RX-API-DMAC7.html)
EP (1) EP3826681A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021531312A (cg-RX-API-DMAC7.html)
CN (1) CN112672762B (cg-RX-API-DMAC7.html)
AU (1) AU2019312144B2 (cg-RX-API-DMAC7.html)
CA (1) CA3107778A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020023323A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022008901A (es) 2020-01-24 2022-08-16 Regeneron Pharma Conjugados de proteinas-compuestos antivirales.
US20210402001A1 (en) * 2020-06-30 2021-12-30 David I. Cohen Zinc Porters, and their Monoclonal Antibody Conjugates, for the Prevention and Treatment of COVID-19 (SARS-CoV-2), Other Infections, and Cancers
US20230312562A1 (en) * 2020-07-02 2023-10-05 Purdue Research Foundation Tetrahydro-3h-pyrazolo quinolone and tetrahydro-3h-pyrrolo[3,2-f]quinoline -containing compounds and uses thereof
EP4178626A4 (en) * 2020-07-13 2024-08-14 University of Southern California Universal car-nk cell targeting various epitopes of hiv-1 gp160
EP4337663A4 (en) * 2021-05-14 2026-04-15 Purdue Research Foundation BISPECIFIC SMALL MOLECULE-BASED IMMUNE CELL ATTACHMENTS AND THEIR USE IN THE TREATMENT OF ENVELOPED VIRUS INFECTION
KR20240038928A (ko) * 2021-07-28 2024-03-26 리제너론 파마슈티칼스 인코포레이티드 단백질-항바이러스 화합물 접합체
IL316372A (en) * 2022-04-19 2024-12-01 Purdue Research Foundation Double and triple hapten conjugatively coupled double and triple hapten, preparations, manufacturing processes and methods of handling them
CN116375647A (zh) * 2023-01-21 2023-07-04 兰州大学 一种基于Click反应的CAR-T细胞药物递送平台及其构建方法与应用
WO2025085664A1 (en) * 2023-10-17 2025-04-24 Mary Lynn Niedrauer Conjugates, com positions and methods for treating influenza
WO2025133395A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Bicyclic (hetero)arylene wrn inhibitory compounds
WO2026044019A1 (en) * 2024-08-21 2026-02-26 Low Stewart Compositions and methods for treating influenza infection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6692724B1 (en) * 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
IL153218A0 (en) * 2000-06-02 2003-07-06 Univ Texas Ethylenedicysteine (ec) -drug conjugates
WO2002044324A2 (en) * 2000-10-06 2002-06-06 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
WO2009140853A1 (en) * 2008-05-23 2009-11-26 The University Of Hong Kong Combination therapy for the treatment of influenza
CA2790577A1 (en) * 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
DK2568976T3 (en) * 2010-05-10 2016-01-11 Academia Sinica Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses
AU2011314335A1 (en) * 2010-06-25 2013-01-31 Purdue Research Foundation Pathogen detection
US10130714B2 (en) * 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
EP2934532B1 (en) * 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US10975112B2 (en) * 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
CA3019835A1 (en) * 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy

Similar Documents

Publication Publication Date Title
JP4868698B2 (ja) マクロファージが仲介する疾患の治療および診断
JP2023162436A (ja) 抗folr1免疫複合体投与計画
JP2025024041A5 (cg-RX-API-DMAC7.html)
JP2022525704A5 (cg-RX-API-DMAC7.html)
JP2018505674A5 (cg-RX-API-DMAC7.html)
JP2006527193A5 (cg-RX-API-DMAC7.html)
JP2018516854A5 (cg-RX-API-DMAC7.html)
HRP20171580T1 (hr) Ljudska monoklonska protutijela koja su specifična za protein e denga virusa serotipa 1 i njihova upotreba
KR970706018A (ko) 백신 조성물(vaccine compositions)
WO2007134037A3 (en) Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
AU2015258801B2 (en) One-step labeling of antibodies to high specific activity with actinium-225
DE05075555T1 (de) Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern
JP2013534528A (ja) 脂質とコンジュゲートする抗体
KR20200006546A (ko) 항-folr1 면역접합체 및 항-pd-1 항체 조합물
Jagadeesh et al. Antibody drug conjugates (ADCs): changing the treatment landscape of lymphoma
JP2013501807A5 (cg-RX-API-DMAC7.html)
JP2006511620A5 (cg-RX-API-DMAC7.html)
Sharkey et al. Biological considerations for radioimmunotherapy
JP2021501800A5 (cg-RX-API-DMAC7.html)
JP2015529656A5 (cg-RX-API-DMAC7.html)
JP2023511956A5 (cg-RX-API-DMAC7.html)
US9289519B2 (en) Alpha emitting constructs and uses thereof
JP2010529950A5 (cg-RX-API-DMAC7.html)
JPS61197528A (ja) 免疫毒素製剤
Scheinberg Current applications of monoclonal antibodies for the therapy of hematopoietic cancers